Indoco Remedies Ltd

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 March 2026, providing investors with the latest insights into its performance and outlook.

Indoco Remedies Ltd’s share price declined sharply to a fresh 52-week low of Rs.189.25 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company amid a broader market downturn and sector-specific pressures.

Indoco Remedies Ltd’s stock declined to a fresh 52-week low of Rs.194.4 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges that have weighed on investor sentiment and overall performance.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 December 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 18 February 2026, providing investors with the latest insights into its performance and prospects.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 December 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 07 February 2026, providing investors with the latest data to understand the stock’s standing today.

Indoco Remedies Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. The stock’s recent decline of 3.79% on 5 Feb 2026, coupled with deteriorating moving averages and bearish MACD readings, underscores growing investor caution in the Pharmaceuticals & Biotechnology sector.

Indoco Remedies Ltd has experienced a notable shift in price momentum, reflected in a 10.11% surge in its share price to ₹233.00 on 4 Feb 2026. Despite this sharp intraday gain, the pharmaceutical company’s technical indicators present a complex picture, with a transition from bearish to mildly bearish trends and a recent downgrade to a Strong Sell rating by MarketsMOJO. This article analyses the evolving technical landscape and what it means for investors navigating the Pharmaceuticals & Biotechnology sector.

Indoco Remedies Ltd., a Mumbai-based pharmaceutical company with operations spanning 55 countries, reported a consolidated net loss of ₹29.79 crores for Q3 FY26 (October-December 2025), marking a significant deterioration from the ₹7.93 crores loss posted in the previous quarter. The stock surged 11.53% on February 3, 2026, to close at ₹236.00, though this represents a 32.20% decline from its 52-week high of ₹348.10, reflecting persistent investor concerns about the company's ability to return to profitability.

Indoco Remedies Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 245.45, marking a significant 9.22% gain. The pharmaceutical company outpaced its sector and broader market indices amid heightened volatility and positive trading momentum.

Indoco Remedies Ltd witnessed a significant gap up at the opening bell on 3 Feb 2026, surging 6.36% higher than its previous close. This strong start was accompanied by notable intraday volatility and an overall outperformance relative to its sector and the broader market, signalling a shift in trading dynamics after two consecutive days of decline.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 December 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 27 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Indoco Remedies Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Indoco Remedies Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend across multiple timeframes. Despite a marginal uptick in the latest session, the pharmaceutical company’s stock continues to underperform relative to the broader market, reflecting growing investor caution amid deteriorating technical conditions.

Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced notable shifts in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. The stock’s recent price movements and technical indicators suggest a nuanced market assessment amid broader sectoral and benchmark trends.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Dec 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.